Study Stopped
Because the COVID pandemic became less severe (omikron)
COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment
CORDEAL
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or COVID-19 Pandemic Resuscitation Plans and Decisions on Escalation and Limitation of Treatment
1 other identifier
interventional
200
1 country
7
Brief Summary
During the Corona Virus Pandemic health care resources have become scare, and the pandemic has brought forth the need for risk stratification of patients suffering from COVID19 in order to allocate resources appropriately. One of scarcest resources is Intensive Care treatment, mostly related to the need for invasive ventilation or for (post) cardiac arrest care. To identify patients for whom ICU-treatment is most successful and those for whom it would be futile, would allow for installing appropriate advanced care directives for escalation or limitation of treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable covid19
Started Mar 2021
Longer than P75 for not_applicable covid19
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2021
CompletedFirst Posted
Study publicly available on registry
February 8, 2021
CompletedStudy Start
First participant enrolled
March 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2025
CompletedFebruary 15, 2023
February 1, 2023
1.8 years
February 3, 2021
February 13, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
ICU-admissions
number of ICU-admissions at baseline and after implementation of the intervention
before and after the intervention; total duration is 12 weeks.
Secondary Outcomes (3)
Mortality
before and after the intervention; patient follow-up at 30 days and 1 year
Health care professionals' satisfaction
Measurements are repeated, before and after the intervention; total duration is 12 weeks.
Patient satisfaction
Measurement is only done once. In one group of patients before and another group after the intervention; total duration is 12 weeks.
Study Arms (2)
Standard practice
NO INTERVENTIONStandard practice concerning advanced care directives; care as usual
Decision aid implementation
EXPERIMENTALStepped-wedge implementation of the intervention
Interventions
Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
Eligibility Criteria
You may qualify if:
- adults with COVID19 (proven by polymerase chain reaction, or with strong clinical suspicion based on clinical features and/or radiodiagnostics)
You may not qualify if:
- minors
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
OLVG
Amsterdam, North Holland, 1091AC, Netherlands
Maasstad Ziekenhuis
Rotterdam, South Holland, 3079DZ, Netherlands
Amsterdam UMC
Amsterdam, Netherlands
Rijnstate
Arnhem, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
Radboud UMC
Nijmegen, Netherlands
Erasmus MC
Rotterdam, 3015CE, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Anesthesiologist-intensivist
Study Record Dates
First Submitted
February 3, 2021
First Posted
February 8, 2021
Study Start
March 1, 2021
Primary Completion
December 31, 2022
Study Completion
January 31, 2025
Last Updated
February 15, 2023
Record last verified: 2023-02